Cancer Family
Peritoneal Neoplasm
CI-CAN-00000318Explore in graph →
Non-malignant142 active trials5 approved drugs2 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000318Explore in graph →
Clinical trials
592 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03740165 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | completed | Phase 3 | 1,367 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Aug 19, 2026 | clinicaltrials |
| NCT02101788 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | completed | Phase 2 / Phase 3 | 260 | National Cancer Institute (NCI)NIH |
| 2 |
| Aug 4, 2026 |
| clinicaltrials |
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 1,560 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT01506856 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial(iPocc) | completed | Phase 2 / Phase 3 | 655 | Gynecologic Oncology Trial & Investigation ConsortiumNETWORK | 6 | Sep 15, 2023 | clinicaltrials |
| NCT01968213 | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)(ARIEL3) | completed | Phase 3 | 564 | pharmaand GmbHINDUSTRY | 11 | Jun 9, 2023 | clinicaltrials |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | completed | Phase 3 | 349 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT03038100 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(IMagyn050) | completed | Phase 3 | 1,301 | Hoffmann-La RocheINDUSTRY | 22 | Feb 17, 2023 | clinicaltrials |
| NCT01462890 | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer(BOOST) | completed | Phase 3 | 927 | AGO Study GroupOTHER | 6 | Jul 20, 2022 | clinicaltrials |
| NCT02231086 | Adjuvant HIPEC in High Risk Colon Cancer(COLOPEC) | completed | Phase 3 | 204 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT00262990 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | completed | Phase 3 | 829 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 17, 2020 | clinicaltrials |
| NCT00216372 | Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis | completed | Phase 3 | 80 | IpsenINDUSTRY | 3 | Nov 5, 2020 | clinicaltrials |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT00028743 | Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 3 | 819 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 2, 2020 | clinicaltrials |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 1,873 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00011986 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 3 | 4,312 | Gynecologic Oncology GroupNETWORK | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01846611 | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 581 | Janssen Research & Development, LLCINDUSTRY | 10 | Apr 1, 2019 | clinicaltrials |
| NCT00443196 | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | completed | Phase 2 / Phase 3 | 150 | Pierian BiosciencesINDUSTRY | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01015118 | LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer | completed | Phase 3 | 1,366 | Boehringer IngelheimINDUSTRY | 22 | Dec 7, 2017 | clinicaltrials |
| NCT01704651 | Accelerating Gastrointestinal Recovery | completed | Phase 3 | 146 | Jamie N. Bakkum-GamezOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT00382811 | OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer(OVATURE) | completed | Phase 3 | 142 | MEI Pharma, Inc.INDUSTRY | 7 | Jul 18, 2016 | clinicaltrials |
| NCT02728622 | Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane | completed | Phase 3 | 241 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 0 | Apr 5, 2016 | clinicaltrials |
| NCT00043082 | S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer | completed | Phase 3 | 61 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 26, 2015 | clinicaltrials |
| NCT00003120 | S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | completed | Phase 3 | 308 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00850772 | Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer(OPEN) | completed | Phase 3 | 109 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Jun 12, 2014 | clinicaltrials |
| NCT00245050 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer | completed | Phase 3 | 34 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 30, 2011 | clinicaltrials |
| NCT00191646 | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | completed | Phase 3 | 919 | Eli Lilly and CompanyINDUSTRY | 2 | Mar 4, 2011 | clinicaltrials |
| NCT00191607 | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | completed | Phase 3 | 162 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials